ArticleBMC pulmonary medicine2022
Body composition and risk factors associated with sarcopenia in post-COVID patients after moderate or severe COVID-19 infections.
Article in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Prevalence and prognosis of sarcopenia in acute COVID-19 and long COVID: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Functional Recovery of Adults Following Acute COVID-19: A Systematic Review and Meta-Analysis.Physical therapy · 2025Pooled it
- Early Administration of Bosentan in High-Risk COVID-19 Outpatients at Risk of Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Trial.Journal of cachexia, sarcopenia and muscle · 2025Trial
- Telerehabilitation improves cardiorespiratory and muscular fitness and body composition in older people with post-COVID-19 syndrome.Journal of cachexia, sarcopenia and muscle · 2024Trial
- Increased physical performance after personalised physiotherapy and nutritional counselling in adults with post-COVID-19 condition: a feasibility randomised trial.Communications medicine · 2026Article
- Risk factors and nomogram for predicting mechanical ventilation in severe pneumonia.Frontiers in medicine · 2025Article
- COVID-19 long: evaluation of quality of life, sarcopenia and proteinuria.Revista de saude publica · 2025Article
- Article
- Relationship between a body shape index and muscle strength index in Chinese university students: a cross-sectional survey.BMC sports science, medicine & rehabilitation · 2024Article
- Gender-Related Effectiveness of Personalized Post-COVID-19 Rehabilitation.Journal of clinical medicine · 2024Article
- Association between muscle quality index and pulmonary function in post-COVID-19 subjects.BMC pulmonary medicine · 2023Article
- COVID-19 in Older Patients: Assessment of Post-COVID-19 Sarcopenia.Biomedicines · 2023Article
- [Coronavirus disease 2019 and frailty].Zeitschrift fur Gerontologie und Geriatrie · 2022Review
- Prognostic Impact of Myosteatosis on Mortality in Hospitalized Patients with COVID-19.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-COVID-19 syndrome is characterized by diverse symptoms and abnormalities that persist beyond 12 weeks from the onset of acute COVID-19. Severity disease has been associated with more musculoskeletal alterations such as muscle weakness, dyspnea, and distance walking. The aim was to evaluate the impact of invasive mechanical ventilation (IMV) on body composition and investigate risk factors associated with sarcopenia in post-COVID-19 patients three months after moderate or severe COVID-19 infections.
methodsCross-sectional study. 530 patients with PCR-confirmed diagnoses of moderate to severe COVID-19, > 18 years old, oxygen saturation ≤ 93%, PaO
resultsThe mean age was 53.79 ± 12.90 years. IMV subjects had lower phase angle and handgrip strength and higher impedance index, frequency of low muscle mass, and low muscle strength than those without IMV. The risk factors of sarcopenia were > 60 years of age, diabetes, obesity, IMV, and prolonged hospital stay. The multivariate model showed that age > 60 years (OR: 4.91, 95% CI: 2.26-10.63), obesity (OR: 3.73, 95% CI: 1.21-11.54), and interaction between prolonged length of hospital stay and IMV (OR: 2.92; 95% CI: 1.21-7.02) were related to a higher risk of sarcopenia.
conclusionObesity and the interaction between prolonged length of hospital stay and IMV are associated with a higher risk of sarcopenia at 3 months after severe or moderate COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.